Joe Papa, chief executive  and president of Perrigo, which is fighitng off the unwatned advances of rival Mylan. Photograph: Brenda Fitzsimons / THE IRISH TIMES

Mylan appeared to hit a significant hurdle in its quest to buy a fellow drug maker, Perrigo, when an influential advisory firm recommended Friday morn(...)

Robert J. Coury, vice chairman and chief executive officer of Mylan told investors he may sweeten the company’s cash-and-stock offer for  Perrigo, which has rejected Mylan’s most recent offer of $75 in cash and 2.3 Mylan shares for each Perrigo share. (Photograph: Mannie Garcia/Bloomberg News)

Mylan’s chairman told investors he may sweeten the company’s cash-and-stock offer for Irish headquartered Perrigo by adding terms to reduce the risk (...)

Robert Coury, chief executive of Mylan pharmacutical company. Photograph: Alan Betson / THE IRISH TIMES

Generic drugmaker Mylan says it will take its $31 billion offer for Perrigo directly to shareholders, in what is set to be one of the most high-profil(...)

Joe Papa CEO and president of Perrigo, which has rejected a $29 billion bid from rival Mylan. Photograph: Brenda Fitzsimons / THE IRISH TIMES

Dublin-based Perrigo has rejected a $29 billion bid from generics group Mylan. The company said its board unanimously rejected the $205 per share offe(...)

Teva factory sign on its plant in Jerusalem: Teva says its stock-and-cash offer of $82 a share represented a 48 per cent premium to Mylan’s stock price on March 10th, which it said was the last day of trading prior to the widespread speculation. Photograph: Menahem Kahana

Generic drugmaker Teva Pharmaceutical Industries Ltd yesterday proposed buying Mylan for $40 billion, saying it was a better deal than the smaller riv(...)

An employee collects newly-manufactured pills at the tablet production plant at Teva Pharmaceutical Industries Ltd.’s headquarters in Jerusalem. Photograph: Adam Reynolds/Bloomberg

Generic drugmaker Teva Pharmaceutical Industries said on Tuesday that it had proposed buying rival Mylan for $82.00 per share in a mix of stock and c(...)

Teva’s acquisition of Auspex is part of a deal-making surge in the industry as drugmakers seek new products to reinforce their own pipelines of experimental treatments. Photographer: Adam Reynolds/Bloomberg

Teva Pharmaceutical Industries has agreed to buy Auspex Pharmaceuticals for about $3.5 billion in cash to bolster its business of making drugs to trea(...)

Former Teva chief executive Jeremy Levin. Photograph: Nir Elias/Reuters

Teva Pharmaceutical Industries, the world’s largest generic drugmaker, said its chief executive Jeremy Levin was stepping down and finance chief Eyal (...)

Liquidators in a case against Micheal Fingleton and four former  Irish Nationwide directors claim and ’unusual management structure operated in the company.

Businesses that fail to manage conflict and litigation proactively may find themselves embroiled in lengthy, expensive battles with their clients, (...)

Pfizer has settled a $2.15 billion settlement lawsuit with Teva  and Sun Pharmaceuticals. Photo: Bloomberg

Pfizer has reached a $2.15 billion settlement with Teva Pharmaceutical Industries and Sun Pharmaceutical Industries after an almost 10- year dispute o(...)